Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. - Concepedia

Concepedia

Publication | Closed Access

Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.

77

Citations

0

References

1997

Year

Janice P. Dutcher, Richard I. Fisher, Geoffrey R. Weiss, Frederick R. Aronson, Kim Margolin, Arthur C. Louie, J W Mier, Geralyn Caliendo, J. A. Sosman, John R. Eckardt,

Abstract

SC rIL-2 plus IFN-a2B is tolerated in the outpatient setting with frequent dose adjustments. The overall response rate of this regimen is similar to that seen with high-dose rIL-2 alone; however, the response duration appears to be shorter.